Netherlands· NL-546e854bf87b
Veoza 45 mg filmomhulde tabletten
A fezolinetant product containing fezolinetant, registered in Netherlands by Astellas Pharma Europe B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Fezolinetant is registered in 14 of 19 countries.
Countries holding a registration under ATC G02CX06 (fezolinetant), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Fezolinetant · ATC G02CX06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of fezolinetant costs, country by country.
Normalised to the WHO defined daily dose (45 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Fezolinetant · price per daily dose (45 mg)
USD · FX 28 Sept 2026
- ES Spain$3.02
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- FEZOLINETANT
- Manufacturer
- Astellas Pharma Europe B.V.
- Country
- Netherlands (NL)
- ATC code
- G02CX06
- ATC class
- Fezolinetant
- Defined daily dose
- 45 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1771
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Fezolinetant in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVEOZAAstellas Pharma Europe B.V., Leiden
- United StatesVEOZAHAstellas Pharma US, Inc.
- SwitzerlandVeoza 45 mg, FilmtablettenAstellas Pharma AG
- FranceVEOZA 45 mg, comprimé pelliculéASTELLAS PHARMA EUROPE (PAYS-BAS)
- BelgiumVeoza 45 mgAstellas Pharma Europe
- IcelandVeozaAstellas Pharma Europe B.V.
- NorwayVeozaAstellas Pharma Europe BV
- PolandVeozaAstellas Pharma Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Veoza
- Liechtenstein · Veoza
- Norway · Veoza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bfad13c0-e88e-48d6-a044-53285a2f05c9 GET /v1/drugs/bfad13c0-e88e-48d6-a044-53285a2f05c9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/veoza-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Fezolinetant",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130406",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE ROOD (E 172)",
"MACROGOL 8000",
"MAGNESIUMSTEARAAT (E 470b)",
"MANNITOL (D-) (E 421)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"FEZOLINETANT"
],
"leaflet_url": null,
"authorised_at": "2023/12/07",
"procedure_number": "EMEA/H/C/005851",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1771",
"additional_monitoring": "Y"
}See everything about fezolinetant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.